... Less Than 40000 Additional FOR Votes Required for Integra Merge...IRVINE California October 26 /- IsoTis Inc....The special meeting of stockholders will reconvene at 1.30 p.m. Pacifi...Of the approximately 3.7 million shares present in person or by proxy...

IRVINE, California, October 26 /PRNewswire-FirstCall/ -- IsoTis, Inc.
(NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that
it has adjourned its special meeting of stockholders again, to Monday,
October 29, 2007, to approve the acquisition of IsoTis by Integra
LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") pursuant to an
agreement and plan of merger dated as of August 6, 2007.

The special meeting of stockholders will reconvene at 1.30 p.m. Pacific
time on Monday, October 29, 2007 at the offices of Latham & Watkins LLP, at
650 Town Centre Drive, 20th floor, Costa Mesa, CA.

Of the approximately 3.7 million shares present in person or by proxy
at today's meeting, approximately 3.5 million shares voted "for" the merger
with Integra, representing approximately 94.5% of the votes cast to date
and approximately 49.5% of all outstanding shares at the record date.

If insufficient votes are cast in favour of the Integra merger at the
reconvened meeting to approve the acquisition, IsoTis may adjourn the
meeting again, or call a new meeting to be held in late November 2007, with
a new record date for the stockholders entitled to vote.

The IsoTis Board of Directors continues to believe unanimously that the
interests of IsoTis' stockholders are best served by the acquisition by
Integra, and that there are no feasible alternatives for the company and
its stockholders. If IsoTis is unable to obtain the vote necessary to
approve the proposed transaction, the company believes it will have to seek
bankruptcy protection.

About IsoTis

IsoTis is an orthobiologics company that develops, manufactures and
markets proprietary products for the treatment of musculoskeletal diseases
and disorders. IsoTis' current orthobiologics products are bone graft
substitutes that promote the regeneration of bone and are used to repair
natural, trauma-related and surgically-created defects common in
orthopaedic procedures, including spinal fusions. IsoTis' current
commercial business is highlighted by its Accell line of products, which
the company believes represents the next generation in bone graft
substitution.

On August 7, 2007 Integra and IsoTis announced that they have reached a
definitive agreement to create a global orthobiologics leader. The
combination would create a comprehensive orthobiologics portfolio, one of
the largest sales organizations focused on orthobiologics in the US, and
multiple cross-selling opportunities. The transaction is subject to
approval of IsoTis' stockholders, as well as other closing conditions and
approvals. Upon closing, IsoTis will become a wholly-owned subsidiary of
Integra and Integra will be one of the largest companies in the world
focused on advanced technology in orthobiologics.

Forward-Looking Statements

Certain statements in this press release are "forward-looking
statements" within the meaning of Section 21E of the Securities Exchange
Act of 1934, as amended, including those that refer to management's plans
and expectations for, among other things, future operations, strategies,
prospects, performance and financial condition and IsoTis' proposed
acquisition by Integra. Words such as "strategy," "expects," "plans,"
"anticipates," "believes," "may," "will," "might," "could," "would,"
"continues," "estimates," "intends," "pursues," "projects," "goals,"
"targets" or the negative or other variations thereof and other words of
similar meaning are intended to identify such forward-looking statements.
One can also identify them by the fact that they do not relate strictly to
historical or current facts. Such statements are based on the current
expectations and projections of the management of IsoTis only. Undue
reliance should not be placed on these statements because, by their nature,
they are subject to known and unknown risks and can be affected by factors
that are beyond the control of IsoTis. Actual results could differ
materially from current expectations and projections. Any forward-looking
statements are made pursuant to the Private Securities Litigation Reform
Act of 1995 and, as such, speak only as of the date made. IsoTis undertakes
no obligation to publicly update any forward-looking statements, whether as
a result of new information, future events or otherwise.

A special stockholder meeting was convened on October 11, 2007,
adjourned to October 23, 2007, again adjourned to October 26, 2007, and now
adjourned to October 29, 2007 to obtain stockholder approval of the
proposed transaction. IsoTis has filed with the Securities and Exchange
Commission and distributed to its stockholders a definitive proxy statement
and other relevant documents in connection with the special stockholder
meeting for the proposed transaction. IsoTis stockholders are urged to read
the definitive proxy statement and other relevant materials when they
become available because they will contain important information about
IsoTis, Integra and the proposed transaction. Investors may obtain a free
copy of these materials and other documents filed by IsoTis with the
Securities and Exchange Commission at the SEC's website at
http://www.sec.gov, at IsoTis' Website at http://www.isotis.com or by
sending a written request to IsoTis at 2 Goodyear, Irvine, California
92618, Attention: Chief Financial Officer.

IsoTis and its directors, executive officers and certain other members
of management and employees may be deemed to be participants in soliciting
proxies from its stockholders in favour of the proposed merger. Information
regarding the persons who may, under the rules of the SEC, be considered to
be participants in the solicitation of IsoTis' stockholders in connection
with the proposed transaction will be set forth in IsoTis' revised
definitive proxy statement for its special meeting. Additional information
regarding these individuals and any interest they have in the proposed
transaction is set forth in the revised definitive proxy statement when it
is filed with the SEC.

(Date:10/12/2017)... ... October 12, 2017 , ... ... Lithuania, announced today that they have entered into a multiyear collaboration to identify ... CRISPR researchers with additional tools for gene editing across all applications. , Under ...

(Date:10/12/2017)... ... October 12, 2017 , ... ... the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life, ... in analytical testing are being attributed to new regulatory requirements for all new ...

(Date:10/11/2017)... , ... October 11, 2017 , ... ... gene in its endogenous context, enabling overexpression experiments and avoiding the use of ... small RNA guides is transformative for performing systematic gain-of-function studies. , This ...

(Date:10/11/2017)... ... October 11, 2017 , ... ... today it will be hosting a Webinar titled, “Pathology is going digital. Is ... , on digital pathology adoption best practices and how Proscia improves lab economics ...

(Date:5/23/2017)... GENOA, Italy , May 23, 2017 Hunova, the first robotic ... and trunk, has been officially launched in Genoa, Italy ... Europe and the USA . The ... launched on the market by the IIT spin-off Movendo Technology thanks to ... view the Multimedia News Release, please click: ...

(Date:5/6/2017)... May 5, 2017 RAM Group ... a new breakthrough in biometric authentication based on ... mechanical properties to perform biometric authentication. These new sensors ... material created by Ram Group and its partners. This ... transportation, supply chains and security. Ram Group is ...

(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017 Socionext Inc., a ... prototype of a media edge server, the M820, which features the ... face recognition software provided by Tera Probe, Inc., will be showcased ... and at the NAB show at the Las Vegas ... ...